Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sepracor-Looks very promising -- Ignore unavailable to you. Want to Upgrade?

To: j_fir2 who wrote (2543)	4/27/1999 12:46:00 PM
From: Don Miller	Read Replies (1) \| Respond to of 10280

Looked for News causing todays decline, FYI It only mentions a few stocks, SEPR is one of them, Don _______________________________________________________ AMEX LISTS MERRILL LYNCH PRINCIPAL PROTECTED NOTES TIED TO THE PERFORMANCE TUESDAY, APRIL 27, 1999 12:19 PM EST - PRNewswire of a Portfolio of Pharmaceutical Stocks; New $22.6 Million Issue Offers Exposure to Three Prominent Drug Stocks Through Single Security NEW YORK, April 27 /PRNewswire/ -- The American Stock Exchange today began trading Merrill Lynch & Co., Inc. 0.25%, Principal Protected Notes, tied to the performance of a basket of drug stocks, which include Pfizer Inc., Warner-Lambert Co. and Sepracor Inc. Listed under the ticker symbol MLD.A, the new seven-year securities were issued at $1,094.39 each. The Notes offer upside participation in the collective performance of the drug stock portfolio, along with the assurance that at least 100% of the principal amount will be returned at maturity on April 27, 2006. The issuer may redeem the Notes on or after April 27, 2002. Holders will receive semi-annual interest payments based on an annual rate of 0.25% on the $1,000 face amount for each note. At maturity, holders are entitled to receive an amount equal to the greater of: -- The sum of the products of the share multipliers and the average closing prices of the portfolio of stocks, or -- The Principal Amount of $1,000 plus accrued interest The issuer for the new security is Merrill Lynch & Co., Inc. The underwriter for the listing is Merrill Lynch & Co. and the Amex Specialist unit is Spear, Leeds & Kellogg. Pfizer Inc. (NYSE:PFE), based in New York City, is a research-based pharmaceutical company that discovers, develops, manufactures and markets medicines for humans and animals worldwide. Warner-Lambert Company (NYSE:WLA), based in Morris Plains, New Jersey, discovers, develops, manufactures, and markets pharmaceutical, consumer healthcare and confectionery products. Sepracor Inc. (Nasdaq:SEPR), based in Marlborough, Massachusetts, develops and commercializes potentially improved versions of widely prescribed drugs. The Nasdaq-Annex Market Group (SM), which operates The Nasdaq Stock Market(R) and The American Stock Exchange(R), is a subsidiary of the National Association of Securities Dealers, Inc. (NASD(R)), the largest securities-industry, self-regulatory organization in the United States. The union of Nasdaq(R) and Amex(R) creates the world's first financial market that brings together central auction specialist and multiple Market Maker systems. The Amex trades options on 29 broad-based and sector indexes and 1,087 domestic and foreign stocks, as well as Long-term Equity AnticiPation Securities (R)(LEAPS(R)) on 121 stocks. Amex is a leader in listing warrants on indexes, hybrid instruments and other structured products. For more information about Nasdaq-Amex, visit the Nasdaq-Amex Web site at nasdaq-amex.com or the Nasdaq-Amex Newsroom(SM) at nasdaq-amexnews.com. SOURCE American Stock Exchange 04/27/99 /CONTACT: Stephan Pechdimaldji of American Stock Exchange, 212-306-1489/ Web site: nasdaq-amex.com Web site: nasdaq-amexnews.com (PFE WLA SEPR MLD.A) CO: Merrill Lynch & Co., Inc.; American Stock Exchange ST: New York IN: FIN SU: SEPR 963/4 37/16 RELATED SYMBOLS WLA 685/16 17/16 MLF 111/8 UNCH PFE 1213/8 23/8 News Provided By COMTEX